Stalicla Gains CHF 2M Funding from Addex for Neurodevelopmental Precision Medicine Programs

Stalicla, a Geneva-based biotech firm specializing in precision medicine for neurodevelopmental and neuropsychiatric disorders, has successfully closed a CHF 2 million financing round. This funding was spearheaded by Addex Therapeutics and is designed to sustain Stalicla’s operations and further develop its programs in neurodevelopmental disorders. The financing is a precursor to the company's upcoming Series C funding round and the strategic partnering of key programs. Notably, this investment demonstrates the strong confidence investors have in Stalicla’s DEPI precision neuro platform and its precision autism assets, STP1 and STP2.

Stalicla is also advancing its STP7 program, centered around mavoglurant, the most clinically advanced mGluR5 negative allosteric modulator. This program recently completed a Phase 3 enabling drug-drug interaction study in October 2024. The ongoing Phase 3 development is financially backed by the National Institute of Health-National Institute on Drug Abuse (NIH-NIDA) through a Collaborative Research and Development Agreement.

An important part of this financing deal involves the appointment of Tim Dyer to Stalicla's Board of Directors, where he will serve as Chairman. Lynn Durham, CEO of Stalicla, commented on the significance of the financing, stating that it represents a crucial step in securing the company’s path towards several key milestones, including the forthcoming Series C financing. Durham expressed gratitude to the Addex-led syndicate for their support, which will enable the company to continue advancing its precision medicine programs and prepare for groundbreaking clinical trials in autism and substance use disorders.

Tim Dyer, CEO of Addex and newly appointed Chairman of Stalicla, praised Stalicla's achievements in establishing a leading precision medicine platform for neurodevelopmental disorders. He emphasized the value that Stalicla has added to its assets, particularly the Phase 3 ready substance use disorder asset, STP7. Dyer expressed his enthusiasm for supporting Lynn Durham and her team in bringing vital medicines to patients.

Stalicla has successfully raised over $50 million in equity and more than $30 million in non-dilutive funding to date. The company has constructed a clinically validated neuro precision development platform that effectively identifies stratified patient subgroups, facilitating the advancement of personalized treatment options. Currently, Stalicla is preparing to initiate Phase 2 trials for its primary neurodevelopmental disorder asset, STP1, along with a second asset targeting specific autism subpopulations. Additionally, STP7 (Mavoglurant) is progressing towards Phase 3 trials, with complete funding provided by the US government.

Addex Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Its lead drug candidate, dipraglurant, an mGlu5 negative allosteric modulator, is being evaluated for potential use in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex is also involved in substance use disorder treatments through its partnership with Indivior. Furthermore, Addex is independently advancing a GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is working on allosteric modulator programs for various neurological conditions.

This financing marks a significant milestone for Stalicla, securing the resources needed to push forward with its innovative approaches in treating neurodevelopmental disorders. With the strategic support from Addex Therapeutics and the leadership of Tim Dyer, Stalicla is well-positioned to make substantial progress in precision medicine and deliver new treatment options to patients.